Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
This is a phase III randomized study which compares two different regimens of chemotherapy. The purpose of the study is to determine which of the two regimens will make the tumor smaller or disappear, and for how long. In addition the disease-related symptoms will be evaluated. The safety of the drugs will be determined based upon evaluation of the side effects
Breast Neoplasms
DRUG: gemcitabine|DRUG: capecitabine|DRUG: docetaxel
Progression free survival. The final analysis will occur when 250 patients have progressed or died.
Overall toxicity|Quality of Life|Overall Survival|Overall Response Rate|Time to Treatment Failure
This is a phase III randomized study which compares two different regimens of chemotherapy. The purpose of the study is to determine which of the two regimens will make the tumor smaller or disappear, and for how long. In addition the disease-related symptoms will be evaluated. The safety of the drugs will be determined based upon evaluation of the side effects